nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezetimibe—ABCB1—ovarian cancer	0.186	1	CbGaD
Ezetimibe—UGT2B7—Epirubicin—ovarian cancer	0.0722	0.138	CbGbCtD
Ezetimibe—ABCG2—Topotecan—ovarian cancer	0.0684	0.13	CbGbCtD
Ezetimibe—ABCC3—Doxorubicin—ovarian cancer	0.0444	0.0846	CbGbCtD
Ezetimibe—ABCC2—Paclitaxel—ovarian cancer	0.0375	0.0714	CbGbCtD
Ezetimibe—ABCC2—Carboplatin—ovarian cancer	0.0353	0.0672	CbGbCtD
Ezetimibe—ABCG2—Paclitaxel—ovarian cancer	0.0339	0.0645	CbGbCtD
Ezetimibe—ABCG2—Carboplatin—ovarian cancer	0.0319	0.0607	CbGbCtD
Ezetimibe—ABCC2—Docetaxel—ovarian cancer	0.0271	0.0516	CbGbCtD
Ezetimibe—ABCB1—Topotecan—ovarian cancer	0.0247	0.047	CbGbCtD
Ezetimibe—ABCG2—Docetaxel—ovarian cancer	0.0245	0.0466	CbGbCtD
Ezetimibe—ABCC2—Doxorubicin—ovarian cancer	0.0202	0.0385	CbGbCtD
Ezetimibe—ABCG2—Doxorubicin—ovarian cancer	0.0183	0.0348	CbGbCtD
Ezetimibe—ABCB1—Vinorelbine—ovarian cancer	0.0174	0.0331	CbGbCtD
Ezetimibe—CYP3A4—Topotecan—ovarian cancer	0.0148	0.0282	CbGbCtD
Ezetimibe—ABCB1—Paclitaxel—ovarian cancer	0.0122	0.0233	CbGbCtD
Ezetimibe—CYP3A4—Vinorelbine—ovarian cancer	0.0104	0.0198	CbGbCtD
Ezetimibe—ABCB1—Docetaxel—ovarian cancer	0.00883	0.0168	CbGbCtD
Ezetimibe—CYP3A4—Paclitaxel—ovarian cancer	0.00732	0.0139	CbGbCtD
Ezetimibe—ABCB1—Doxorubicin—ovarian cancer	0.00658	0.0125	CbGbCtD
Ezetimibe—CYP3A4—Docetaxel—ovarian cancer	0.00529	0.0101	CbGbCtD
Ezetimibe—CYP3A4—Doxorubicin—ovarian cancer	0.00394	0.00751	CbGbCtD
Ezetimibe—NPC1L1—testis—ovarian cancer	0.00393	0.0594	CbGeAlD
Ezetimibe—SOAT1—myometrium—ovarian cancer	0.00286	0.0432	CbGeAlD
Ezetimibe—ANPEP—myometrium—ovarian cancer	0.00273	0.0413	CbGeAlD
Ezetimibe—ANPEP—embryo—ovarian cancer	0.00263	0.0397	CbGeAlD
Ezetimibe—SOAT1—uterine cervix—ovarian cancer	0.00222	0.0336	CbGeAlD
Ezetimibe—ANPEP—epithelium—ovarian cancer	0.00214	0.0324	CbGeAlD
Ezetimibe—ANPEP—uterine cervix—ovarian cancer	0.00213	0.0322	CbGeAlD
Ezetimibe—SOAT1—decidua—ovarian cancer	0.00212	0.032	CbGeAlD
Ezetimibe—ANPEP—decidua—ovarian cancer	0.00203	0.0306	CbGeAlD
Ezetimibe—SOAT1—endometrium—ovarian cancer	0.00201	0.0304	CbGeAlD
Ezetimibe—UGT2B15—female reproductive system—ovarian cancer	0.00194	0.0293	CbGeAlD
Ezetimibe—ANPEP—endometrium—ovarian cancer	0.00192	0.0291	CbGeAlD
Ezetimibe—SOAT1—gonad—ovarian cancer	0.00187	0.0282	CbGeAlD
Ezetimibe—ANPEP—uterus—ovarian cancer	0.00177	0.0268	CbGeAlD
Ezetimibe—SOAT1—female reproductive system—ovarian cancer	0.00167	0.0252	CbGeAlD
Ezetimibe—ANPEP—female reproductive system—ovarian cancer	0.00159	0.0241	CbGeAlD
Ezetimibe—SOAT1—bone marrow—ovarian cancer	0.00157	0.0238	CbGeAlD
Ezetimibe—SOAT1—female gonad—ovarian cancer	0.00152	0.0229	CbGeAlD
Ezetimibe—SOAT1—vagina—ovarian cancer	0.00151	0.0228	CbGeAlD
Ezetimibe—ANPEP—bone marrow—ovarian cancer	0.0015	0.0227	CbGeAlD
Ezetimibe—ANPEP—female gonad—ovarian cancer	0.00145	0.0219	CbGeAlD
Ezetimibe—ANPEP—vagina—ovarian cancer	0.00144	0.0218	CbGeAlD
Ezetimibe—SOAT1—testis—ovarian cancer	0.00134	0.0203	CbGeAlD
Ezetimibe—ANPEP—testis—ovarian cancer	0.00129	0.0194	CbGeAlD
Ezetimibe—UGT2B7—female reproductive system—ovarian cancer	0.00118	0.0179	CbGeAlD
Ezetimibe—ABCC3—decidua—ovarian cancer	0.00101	0.0153	CbGeAlD
Ezetimibe—SOAT1—lymph node—ovarian cancer	0.000974	0.0147	CbGeAlD
Ezetimibe—UGT2B7—testis—ovarian cancer	0.000955	0.0144	CbGeAlD
Ezetimibe—ANPEP—lymph node—ovarian cancer	0.000932	0.0141	CbGeAlD
Ezetimibe—SLCO1B1—female reproductive system—ovarian cancer	0.000837	0.0127	CbGeAlD
Ezetimibe—ABCC3—female reproductive system—ovarian cancer	0.000794	0.012	CbGeAlD
Ezetimibe—ABCG2—myometrium—ovarian cancer	0.000794	0.012	CbGeAlD
Ezetimibe—ABCC3—female gonad—ovarian cancer	0.000723	0.0109	CbGeAlD
Ezetimibe—ABCC3—testis—ovarian cancer	0.000641	0.00969	CbGeAlD
Ezetimibe—ABCC2—female reproductive system—ovarian cancer	0.000635	0.00959	CbGeAlD
Ezetimibe—ABCG2—uterine cervix—ovarian cancer	0.000618	0.00934	CbGeAlD
Ezetimibe—ABCG2—decidua—ovarian cancer	0.000588	0.0089	CbGeAlD
Ezetimibe—ABCG2—endometrium—ovarian cancer	0.000559	0.00845	CbGeAlD
Ezetimibe—ABCG2—uterus—ovarian cancer	0.000515	0.00778	CbGeAlD
Ezetimibe—ABCC2—testis—ovarian cancer	0.000512	0.00774	CbGeAlD
Ezetimibe—ABCC3—lymph node—ovarian cancer	0.000465	0.00702	CbGeAlD
Ezetimibe—ABCG2—bone marrow—ovarian cancer	0.000437	0.0066	CbGeAlD
Ezetimibe—ABCG2—female gonad—ovarian cancer	0.000421	0.00637	CbGeAlD
Ezetimibe—ABCG2—vagina—ovarian cancer	0.000418	0.00633	CbGeAlD
Ezetimibe—ABCB1—myometrium—ovarian cancer	0.000391	0.00592	CbGeAlD
Ezetimibe—ABCB1—embryo—ovarian cancer	0.000376	0.00569	CbGeAlD
Ezetimibe—ABCG2—testis—ovarian cancer	0.000373	0.00565	CbGeAlD
Ezetimibe—ABCC2—lymph node—ovarian cancer	0.000371	0.00561	CbGeAlD
Ezetimibe—CYP3A4—female reproductive system—ovarian cancer	0.000322	0.00487	CbGeAlD
Ezetimibe—ABCB1—epithelium—ovarian cancer	0.000307	0.00464	CbGeAlD
Ezetimibe—ABCB1—uterine cervix—ovarian cancer	0.000305	0.0046	CbGeAlD
Ezetimibe—ABCB1—decidua—ovarian cancer	0.00029	0.00439	CbGeAlD
Ezetimibe—ABCB1—endometrium—ovarian cancer	0.000275	0.00416	CbGeAlD
Ezetimibe—ABCG2—lymph node—ovarian cancer	0.000271	0.00409	CbGeAlD
Ezetimibe—ABCB1—gonad—ovarian cancer	0.000255	0.00386	CbGeAlD
Ezetimibe—ABCB1—uterus—ovarian cancer	0.000254	0.00384	CbGeAlD
Ezetimibe—ABCB1—female reproductive system—ovarian cancer	0.000228	0.00345	CbGeAlD
Ezetimibe—ABCB1—bone marrow—ovarian cancer	0.000215	0.00326	CbGeAlD
Ezetimibe—ABCB1—female gonad—ovarian cancer	0.000208	0.00314	CbGeAlD
Ezetimibe—ABCB1—vagina—ovarian cancer	0.000206	0.00312	CbGeAlD
Ezetimibe—Rash—Melphalan—ovarian cancer	0.000185	0.00129	CcSEcCtD
Ezetimibe—Dermatitis—Melphalan—ovarian cancer	0.000185	0.00128	CcSEcCtD
Ezetimibe—Cough—Paclitaxel—ovarian cancer	0.000184	0.00128	CcSEcCtD
Ezetimibe—ABCB1—testis—ovarian cancer	0.000184	0.00278	CbGeAlD
Ezetimibe—Asthenia—Vinorelbine—ovarian cancer	0.000184	0.00128	CcSEcCtD
Ezetimibe—Hypertension—Paclitaxel—ovarian cancer	0.000183	0.00127	CcSEcCtD
Ezetimibe—Alopecia—Docetaxel—ovarian cancer	0.000182	0.00126	CcSEcCtD
Ezetimibe—Pruritus—Vinorelbine—ovarian cancer	0.000181	0.00126	CcSEcCtD
Ezetimibe—Breast disorder—Epirubicin—ovarian cancer	0.000181	0.00126	CcSEcCtD
Ezetimibe—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.000181	0.00125	CcSEcCtD
Ezetimibe—Mental disorder—Docetaxel—ovarian cancer	0.00018	0.00125	CcSEcCtD
Ezetimibe—Chest pain—Paclitaxel—ovarian cancer	0.00018	0.00125	CcSEcCtD
Ezetimibe—Arthralgia—Paclitaxel—ovarian cancer	0.00018	0.00125	CcSEcCtD
Ezetimibe—Myalgia—Paclitaxel—ovarian cancer	0.00018	0.00125	CcSEcCtD
Ezetimibe—Nasopharyngitis—Epirubicin—ovarian cancer	0.000179	0.00125	CcSEcCtD
Ezetimibe—Erythema—Docetaxel—ovarian cancer	0.000179	0.00124	CcSEcCtD
Ezetimibe—Malnutrition—Docetaxel—ovarian cancer	0.000179	0.00124	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000179	0.00124	CcSEcCtD
Ezetimibe—Nausea—Topotecan—ovarian cancer	0.000178	0.00124	CcSEcCtD
Ezetimibe—Discomfort—Paclitaxel—ovarian cancer	0.000178	0.00123	CcSEcCtD
Ezetimibe—Gastritis—Epirubicin—ovarian cancer	0.000178	0.00123	CcSEcCtD
Ezetimibe—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.000177	0.00123	CcSEcCtD
Ezetimibe—Muscular weakness—Epirubicin—ovarian cancer	0.000177	0.00123	CcSEcCtD
Ezetimibe—Dry mouth—Paclitaxel—ovarian cancer	0.000176	0.00122	CcSEcCtD
Ezetimibe—Diarrhoea—Vinorelbine—ovarian cancer	0.000175	0.00122	CcSEcCtD
Ezetimibe—Nausea—Melphalan—ovarian cancer	0.000174	0.00121	CcSEcCtD
Ezetimibe—Confusional state—Paclitaxel—ovarian cancer	0.000174	0.00121	CcSEcCtD
Ezetimibe—Influenza—Epirubicin—ovarian cancer	0.000173	0.0012	CcSEcCtD
Ezetimibe—Back pain—Docetaxel—ovarian cancer	0.000173	0.0012	CcSEcCtD
Ezetimibe—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000173	0.0012	CcSEcCtD
Ezetimibe—Muscle spasms—Docetaxel—ovarian cancer	0.000172	0.0012	CcSEcCtD
Ezetimibe—Eosinophilia—Epirubicin—ovarian cancer	0.000172	0.00119	CcSEcCtD
Ezetimibe—Liver function test abnormal—Doxorubicin—ovarian cancer	0.000171	0.00119	CcSEcCtD
Ezetimibe—Infection—Paclitaxel—ovarian cancer	0.000171	0.00119	CcSEcCtD
Ezetimibe—Pancreatitis—Epirubicin—ovarian cancer	0.00017	0.00118	CcSEcCtD
Ezetimibe—Dizziness—Vinorelbine—ovarian cancer	0.00017	0.00118	CcSEcCtD
Ezetimibe—Nervous system disorder—Paclitaxel—ovarian cancer	0.000169	0.00117	CcSEcCtD
Ezetimibe—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000169	0.00117	CcSEcCtD
Ezetimibe—Breast disorder—Doxorubicin—ovarian cancer	0.000168	0.00117	CcSEcCtD
Ezetimibe—Skin disorder—Paclitaxel—ovarian cancer	0.000168	0.00116	CcSEcCtD
Ezetimibe—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.000167	0.00116	CcSEcCtD
Ezetimibe—Nasopharyngitis—Doxorubicin—ovarian cancer	0.000166	0.00115	CcSEcCtD
Ezetimibe—Anaemia—Docetaxel—ovarian cancer	0.000166	0.00115	CcSEcCtD
Ezetimibe—Gastritis—Doxorubicin—ovarian cancer	0.000164	0.00114	CcSEcCtD
Ezetimibe—Muscular weakness—Doxorubicin—ovarian cancer	0.000164	0.00114	CcSEcCtD
Ezetimibe—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000164	0.00114	CcSEcCtD
Ezetimibe—Vomiting—Vinorelbine—ovarian cancer	0.000163	0.00113	CcSEcCtD
Ezetimibe—Rash—Vinorelbine—ovarian cancer	0.000162	0.00112	CcSEcCtD
Ezetimibe—Dermatitis—Vinorelbine—ovarian cancer	0.000162	0.00112	CcSEcCtD
Ezetimibe—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000161	0.00112	CcSEcCtD
Ezetimibe—Headache—Vinorelbine—ovarian cancer	0.000161	0.00112	CcSEcCtD
Ezetimibe—Influenza—Doxorubicin—ovarian cancer	0.00016	0.00111	CcSEcCtD
Ezetimibe—Eosinophilia—Doxorubicin—ovarian cancer	0.000159	0.0011	CcSEcCtD
Ezetimibe—Palpitations—Docetaxel—ovarian cancer	0.000158	0.0011	CcSEcCtD
Ezetimibe—Photosensitivity reaction—Epirubicin—ovarian cancer	0.000158	0.0011	CcSEcCtD
Ezetimibe—Pancreatitis—Doxorubicin—ovarian cancer	0.000157	0.00109	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000157	0.00109	CcSEcCtD
Ezetimibe—Cough—Docetaxel—ovarian cancer	0.000156	0.00109	CcSEcCtD
Ezetimibe—Insomnia—Paclitaxel—ovarian cancer	0.000156	0.00108	CcSEcCtD
Ezetimibe—Paraesthesia—Paclitaxel—ovarian cancer	0.000155	0.00108	CcSEcCtD
Ezetimibe—Hypertension—Docetaxel—ovarian cancer	0.000155	0.00107	CcSEcCtD
Ezetimibe—Infestation NOS—Epirubicin—ovarian cancer	0.000155	0.00107	CcSEcCtD
Ezetimibe—Infestation—Epirubicin—ovarian cancer	0.000155	0.00107	CcSEcCtD
Ezetimibe—Dyspnoea—Paclitaxel—ovarian cancer	0.000154	0.00107	CcSEcCtD
Ezetimibe—Chest pain—Docetaxel—ovarian cancer	0.000153	0.00106	CcSEcCtD
Ezetimibe—Arthralgia—Docetaxel—ovarian cancer	0.000153	0.00106	CcSEcCtD
Ezetimibe—Myalgia—Docetaxel—ovarian cancer	0.000153	0.00106	CcSEcCtD
Ezetimibe—Nausea—Vinorelbine—ovarian cancer	0.000152	0.00106	CcSEcCtD
Ezetimibe—Dyspepsia—Paclitaxel—ovarian cancer	0.000152	0.00105	CcSEcCtD
Ezetimibe—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000152	0.00105	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000151	0.00105	CcSEcCtD
Ezetimibe—Jaundice—Epirubicin—ovarian cancer	0.000151	0.00105	CcSEcCtD
Ezetimibe—Decreased appetite—Paclitaxel—ovarian cancer	0.00015	0.00104	CcSEcCtD
Ezetimibe—Dry mouth—Docetaxel—ovarian cancer	0.000149	0.00104	CcSEcCtD
Ezetimibe—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000149	0.00104	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000149	0.00103	CcSEcCtD
Ezetimibe—Fatigue—Paclitaxel—ovarian cancer	0.000149	0.00103	CcSEcCtD
Ezetimibe—Pain—Paclitaxel—ovarian cancer	0.000148	0.00102	CcSEcCtD
Ezetimibe—Constipation—Paclitaxel—ovarian cancer	0.000148	0.00102	CcSEcCtD
Ezetimibe—Confusional state—Docetaxel—ovarian cancer	0.000147	0.00102	CcSEcCtD
Ezetimibe—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000146	0.00102	CcSEcCtD
Ezetimibe—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000146	0.00102	CcSEcCtD
Ezetimibe—Anaphylactic shock—Docetaxel—ovarian cancer	0.000146	0.00102	CcSEcCtD
Ezetimibe—Infection—Docetaxel—ovarian cancer	0.000145	0.00101	CcSEcCtD
Ezetimibe—Sinusitis—Epirubicin—ovarian cancer	0.000145	0.00101	CcSEcCtD
Ezetimibe—Nervous system disorder—Docetaxel—ovarian cancer	0.000143	0.000996	CcSEcCtD
Ezetimibe—Thrombocytopenia—Docetaxel—ovarian cancer	0.000143	0.000994	CcSEcCtD
Ezetimibe—Infestation NOS—Doxorubicin—ovarian cancer	0.000143	0.000994	CcSEcCtD
Ezetimibe—Infestation—Doxorubicin—ovarian cancer	0.000143	0.000994	CcSEcCtD
Ezetimibe—Feeling abnormal—Paclitaxel—ovarian cancer	0.000142	0.000987	CcSEcCtD
Ezetimibe—Skin disorder—Docetaxel—ovarian cancer	0.000142	0.000986	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000141	0.00098	CcSEcCtD
Ezetimibe—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.00014	0.000974	CcSEcCtD
Ezetimibe—Jaundice—Doxorubicin—ovarian cancer	0.000139	0.000969	CcSEcCtD
Ezetimibe—Hepatitis—Epirubicin—ovarian cancer	0.000139	0.000964	CcSEcCtD
Ezetimibe—Pharyngitis—Epirubicin—ovarian cancer	0.000138	0.000957	CcSEcCtD
Ezetimibe—Urticaria—Paclitaxel—ovarian cancer	0.000137	0.000952	CcSEcCtD
Ezetimibe—Oedema peripheral—Epirubicin—ovarian cancer	0.000137	0.00095	CcSEcCtD
Ezetimibe—Connective tissue disorder—Epirubicin—ovarian cancer	0.000136	0.000947	CcSEcCtD
Ezetimibe—Abdominal pain—Paclitaxel—ovarian cancer	0.000136	0.000947	CcSEcCtD
Ezetimibe—Body temperature increased—Paclitaxel—ovarian cancer	0.000136	0.000947	CcSEcCtD
Ezetimibe—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000135	0.00094	CcSEcCtD
Ezetimibe—Sinusitis—Doxorubicin—ovarian cancer	0.000134	0.000932	CcSEcCtD
Ezetimibe—ABCB1—lymph node—ovarian cancer	0.000133	0.00202	CbGeAlD
Ezetimibe—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000133	0.000925	CcSEcCtD
Ezetimibe—Insomnia—Docetaxel—ovarian cancer	0.000132	0.000918	CcSEcCtD
Ezetimibe—Paraesthesia—Docetaxel—ovarian cancer	0.000131	0.000912	CcSEcCtD
Ezetimibe—Erythema multiforme—Epirubicin—ovarian cancer	0.000131	0.000911	CcSEcCtD
Ezetimibe—Dyspnoea—Docetaxel—ovarian cancer	0.00013	0.000905	CcSEcCtD
Ezetimibe—Flushing—Epirubicin—ovarian cancer	0.000129	0.000895	CcSEcCtD
Ezetimibe—Dyspepsia—Docetaxel—ovarian cancer	0.000129	0.000894	CcSEcCtD
Ezetimibe—Hepatitis—Doxorubicin—ovarian cancer	0.000128	0.000892	CcSEcCtD
Ezetimibe—Pharyngitis—Doxorubicin—ovarian cancer	0.000127	0.000885	CcSEcCtD
Ezetimibe—Decreased appetite—Docetaxel—ovarian cancer	0.000127	0.000883	CcSEcCtD
Ezetimibe—Hypersensitivity—Paclitaxel—ovarian cancer	0.000127	0.000883	CcSEcCtD
Ezetimibe—Oedema peripheral—Doxorubicin—ovarian cancer	0.000127	0.000879	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000126	0.000877	CcSEcCtD
Ezetimibe—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000126	0.000877	CcSEcCtD
Ezetimibe—Fatigue—Docetaxel—ovarian cancer	0.000126	0.000875	CcSEcCtD
Ezetimibe—Angiopathy—Epirubicin—ovarian cancer	0.000126	0.000875	CcSEcCtD
Ezetimibe—Immune system disorder—Epirubicin—ovarian cancer	0.000125	0.000871	CcSEcCtD
Ezetimibe—Mediastinal disorder—Epirubicin—ovarian cancer	0.000125	0.000869	CcSEcCtD
Ezetimibe—Constipation—Docetaxel—ovarian cancer	0.000125	0.000868	CcSEcCtD
Ezetimibe—Pain—Docetaxel—ovarian cancer	0.000125	0.000868	CcSEcCtD
Ezetimibe—Asthenia—Paclitaxel—ovarian cancer	0.000124	0.00086	CcSEcCtD
Ezetimibe—Alopecia—Epirubicin—ovarian cancer	0.000123	0.000852	CcSEcCtD
Ezetimibe—Pruritus—Paclitaxel—ovarian cancer	0.000122	0.000848	CcSEcCtD
Ezetimibe—Mental disorder—Epirubicin—ovarian cancer	0.000122	0.000845	CcSEcCtD
Ezetimibe—Erythema multiforme—Doxorubicin—ovarian cancer	0.000121	0.000843	CcSEcCtD
Ezetimibe—Erythema—Epirubicin—ovarian cancer	0.000121	0.000839	CcSEcCtD
Ezetimibe—Malnutrition—Epirubicin—ovarian cancer	0.000121	0.000839	CcSEcCtD
Ezetimibe—Feeling abnormal—Docetaxel—ovarian cancer	0.000121	0.000837	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Docetaxel—ovarian cancer	0.00012	0.00083	CcSEcCtD
Ezetimibe—Flushing—Doxorubicin—ovarian cancer	0.000119	0.000828	CcSEcCtD
Ezetimibe—Flatulence—Epirubicin—ovarian cancer	0.000119	0.000827	CcSEcCtD
Ezetimibe—Diarrhoea—Paclitaxel—ovarian cancer	0.000118	0.00082	CcSEcCtD
Ezetimibe—Back pain—Epirubicin—ovarian cancer	0.000117	0.000812	CcSEcCtD
Ezetimibe—Angiopathy—Doxorubicin—ovarian cancer	0.000117	0.000809	CcSEcCtD
Ezetimibe—Muscle spasms—Epirubicin—ovarian cancer	0.000116	0.000807	CcSEcCtD
Ezetimibe—Immune system disorder—Doxorubicin—ovarian cancer	0.000116	0.000806	CcSEcCtD
Ezetimibe—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000116	0.000804	CcSEcCtD
Ezetimibe—Abdominal pain—Docetaxel—ovarian cancer	0.000116	0.000803	CcSEcCtD
Ezetimibe—Body temperature increased—Docetaxel—ovarian cancer	0.000116	0.000803	CcSEcCtD
Ezetimibe—Dizziness—Paclitaxel—ovarian cancer	0.000114	0.000792	CcSEcCtD
Ezetimibe—Alopecia—Doxorubicin—ovarian cancer	0.000114	0.000788	CcSEcCtD
Ezetimibe—Mental disorder—Doxorubicin—ovarian cancer	0.000113	0.000781	CcSEcCtD
Ezetimibe—Ill-defined disorder—Epirubicin—ovarian cancer	0.000112	0.000779	CcSEcCtD
Ezetimibe—Erythema—Doxorubicin—ovarian cancer	0.000112	0.000776	CcSEcCtD
Ezetimibe—Malnutrition—Doxorubicin—ovarian cancer	0.000112	0.000776	CcSEcCtD
Ezetimibe—Anaemia—Epirubicin—ovarian cancer	0.000112	0.000776	CcSEcCtD
Ezetimibe—Flatulence—Doxorubicin—ovarian cancer	0.00011	0.000765	CcSEcCtD
Ezetimibe—Vomiting—Paclitaxel—ovarian cancer	0.00011	0.000762	CcSEcCtD
Ezetimibe—Malaise—Epirubicin—ovarian cancer	0.000109	0.000757	CcSEcCtD
Ezetimibe—Rash—Paclitaxel—ovarian cancer	0.000109	0.000755	CcSEcCtD
Ezetimibe—Dermatitis—Paclitaxel—ovarian cancer	0.000109	0.000755	CcSEcCtD
Ezetimibe—Back pain—Doxorubicin—ovarian cancer	0.000108	0.000751	CcSEcCtD
Ezetimibe—Headache—Paclitaxel—ovarian cancer	0.000108	0.00075	CcSEcCtD
Ezetimibe—Hypersensitivity—Docetaxel—ovarian cancer	0.000108	0.000748	CcSEcCtD
Ezetimibe—Muscle spasms—Doxorubicin—ovarian cancer	0.000108	0.000747	CcSEcCtD
Ezetimibe—Palpitations—Epirubicin—ovarian cancer	0.000107	0.000742	CcSEcCtD
Ezetimibe—Cough—Epirubicin—ovarian cancer	0.000105	0.000732	CcSEcCtD
Ezetimibe—Asthenia—Docetaxel—ovarian cancer	0.000105	0.000729	CcSEcCtD
Ezetimibe—Hypertension—Epirubicin—ovarian cancer	0.000104	0.000725	CcSEcCtD
Ezetimibe—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000104	0.00072	CcSEcCtD
Ezetimibe—Pruritus—Docetaxel—ovarian cancer	0.000103	0.000718	CcSEcCtD
Ezetimibe—Anaemia—Doxorubicin—ovarian cancer	0.000103	0.000718	CcSEcCtD
Ezetimibe—Arthralgia—Epirubicin—ovarian cancer	0.000103	0.000714	CcSEcCtD
Ezetimibe—Myalgia—Epirubicin—ovarian cancer	0.000103	0.000714	CcSEcCtD
Ezetimibe—Chest pain—Epirubicin—ovarian cancer	0.000103	0.000714	CcSEcCtD
Ezetimibe—Nausea—Paclitaxel—ovarian cancer	0.000102	0.000712	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000102	0.00071	CcSEcCtD
Ezetimibe—Discomfort—Epirubicin—ovarian cancer	0.000102	0.000706	CcSEcCtD
Ezetimibe—Malaise—Doxorubicin—ovarian cancer	0.000101	0.0007	CcSEcCtD
Ezetimibe—Dry mouth—Epirubicin—ovarian cancer	0.000101	0.000699	CcSEcCtD
Ezetimibe—Diarrhoea—Docetaxel—ovarian cancer	0.0001	0.000695	CcSEcCtD
Ezetimibe—Confusional state—Epirubicin—ovarian cancer	9.95e-05	0.000691	CcSEcCtD
Ezetimibe—Palpitations—Doxorubicin—ovarian cancer	9.88e-05	0.000686	CcSEcCtD
Ezetimibe—Anaphylactic shock—Epirubicin—ovarian cancer	9.86e-05	0.000685	CcSEcCtD
Ezetimibe—Infection—Epirubicin—ovarian cancer	9.8e-05	0.00068	CcSEcCtD
Ezetimibe—Cough—Doxorubicin—ovarian cancer	9.76e-05	0.000678	CcSEcCtD
Ezetimibe—Nervous system disorder—Epirubicin—ovarian cancer	9.67e-05	0.000672	CcSEcCtD
Ezetimibe—Dizziness—Docetaxel—ovarian cancer	9.67e-05	0.000671	CcSEcCtD
Ezetimibe—Thrombocytopenia—Epirubicin—ovarian cancer	9.66e-05	0.000671	CcSEcCtD
Ezetimibe—Hypertension—Doxorubicin—ovarian cancer	9.65e-05	0.00067	CcSEcCtD
Ezetimibe—Skin disorder—Epirubicin—ovarian cancer	9.58e-05	0.000665	CcSEcCtD
Ezetimibe—Myalgia—Doxorubicin—ovarian cancer	9.52e-05	0.000661	CcSEcCtD
Ezetimibe—Arthralgia—Doxorubicin—ovarian cancer	9.52e-05	0.000661	CcSEcCtD
Ezetimibe—Chest pain—Doxorubicin—ovarian cancer	9.52e-05	0.000661	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	9.45e-05	0.000657	CcSEcCtD
Ezetimibe—Discomfort—Doxorubicin—ovarian cancer	9.41e-05	0.000653	CcSEcCtD
Ezetimibe—Dry mouth—Doxorubicin—ovarian cancer	9.31e-05	0.000647	CcSEcCtD
Ezetimibe—Vomiting—Docetaxel—ovarian cancer	9.3e-05	0.000646	CcSEcCtD
Ezetimibe—Rash—Docetaxel—ovarian cancer	9.22e-05	0.00064	CcSEcCtD
Ezetimibe—Dermatitis—Docetaxel—ovarian cancer	9.21e-05	0.00064	CcSEcCtD
Ezetimibe—Confusional state—Doxorubicin—ovarian cancer	9.2e-05	0.000639	CcSEcCtD
Ezetimibe—Headache—Docetaxel—ovarian cancer	9.16e-05	0.000636	CcSEcCtD
Ezetimibe—Anaphylactic shock—Doxorubicin—ovarian cancer	9.13e-05	0.000634	CcSEcCtD
Ezetimibe—Infection—Doxorubicin—ovarian cancer	9.07e-05	0.00063	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Epirubicin—ovarian cancer	8.99e-05	0.000624	CcSEcCtD
Ezetimibe—Nervous system disorder—Doxorubicin—ovarian cancer	8.95e-05	0.000621	CcSEcCtD
Ezetimibe—Thrombocytopenia—Doxorubicin—ovarian cancer	8.94e-05	0.00062	CcSEcCtD
Ezetimibe—Insomnia—Epirubicin—ovarian cancer	8.92e-05	0.000619	CcSEcCtD
Ezetimibe—Skin disorder—Doxorubicin—ovarian cancer	8.86e-05	0.000616	CcSEcCtD
Ezetimibe—Paraesthesia—Epirubicin—ovarian cancer	8.86e-05	0.000615	CcSEcCtD
Ezetimibe—Dyspnoea—Epirubicin—ovarian cancer	8.79e-05	0.000611	CcSEcCtD
Ezetimibe—Nausea—Docetaxel—ovarian cancer	8.69e-05	0.000603	CcSEcCtD
Ezetimibe—Dyspepsia—Epirubicin—ovarian cancer	8.68e-05	0.000603	CcSEcCtD
Ezetimibe—Decreased appetite—Epirubicin—ovarian cancer	8.57e-05	0.000595	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Epirubicin—ovarian cancer	8.52e-05	0.000591	CcSEcCtD
Ezetimibe—Fatigue—Epirubicin—ovarian cancer	8.5e-05	0.00059	CcSEcCtD
Ezetimibe—Constipation—Epirubicin—ovarian cancer	8.43e-05	0.000586	CcSEcCtD
Ezetimibe—Pain—Epirubicin—ovarian cancer	8.43e-05	0.000586	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	8.31e-05	0.000577	CcSEcCtD
Ezetimibe—Insomnia—Doxorubicin—ovarian cancer	8.25e-05	0.000573	CcSEcCtD
Ezetimibe—Paraesthesia—Doxorubicin—ovarian cancer	8.19e-05	0.000569	CcSEcCtD
Ezetimibe—Dyspnoea—Doxorubicin—ovarian cancer	8.14e-05	0.000565	CcSEcCtD
Ezetimibe—Feeling abnormal—Epirubicin—ovarian cancer	8.13e-05	0.000564	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Epirubicin—ovarian cancer	8.07e-05	0.00056	CcSEcCtD
Ezetimibe—Dyspepsia—Doxorubicin—ovarian cancer	8.03e-05	0.000558	CcSEcCtD
Ezetimibe—Decreased appetite—Doxorubicin—ovarian cancer	7.93e-05	0.000551	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Doxorubicin—ovarian cancer	7.88e-05	0.000547	CcSEcCtD
Ezetimibe—Fatigue—Doxorubicin—ovarian cancer	7.87e-05	0.000546	CcSEcCtD
Ezetimibe—Urticaria—Epirubicin—ovarian cancer	7.84e-05	0.000544	CcSEcCtD
Ezetimibe—Constipation—Doxorubicin—ovarian cancer	7.8e-05	0.000542	CcSEcCtD
Ezetimibe—Pain—Doxorubicin—ovarian cancer	7.8e-05	0.000542	CcSEcCtD
Ezetimibe—Abdominal pain—Epirubicin—ovarian cancer	7.8e-05	0.000541	CcSEcCtD
Ezetimibe—Body temperature increased—Epirubicin—ovarian cancer	7.8e-05	0.000541	CcSEcCtD
Ezetimibe—Feeling abnormal—Doxorubicin—ovarian cancer	7.52e-05	0.000522	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Doxorubicin—ovarian cancer	7.46e-05	0.000518	CcSEcCtD
Ezetimibe—Hypersensitivity—Epirubicin—ovarian cancer	7.27e-05	0.000505	CcSEcCtD
Ezetimibe—Urticaria—Doxorubicin—ovarian cancer	7.25e-05	0.000503	CcSEcCtD
Ezetimibe—Body temperature increased—Doxorubicin—ovarian cancer	7.21e-05	0.000501	CcSEcCtD
Ezetimibe—Abdominal pain—Doxorubicin—ovarian cancer	7.21e-05	0.000501	CcSEcCtD
Ezetimibe—Asthenia—Epirubicin—ovarian cancer	7.08e-05	0.000491	CcSEcCtD
Ezetimibe—Pruritus—Epirubicin—ovarian cancer	6.98e-05	0.000485	CcSEcCtD
Ezetimibe—Diarrhoea—Epirubicin—ovarian cancer	6.75e-05	0.000469	CcSEcCtD
Ezetimibe—Hypersensitivity—Doxorubicin—ovarian cancer	6.72e-05	0.000467	CcSEcCtD
Ezetimibe—Asthenia—Doxorubicin—ovarian cancer	6.55e-05	0.000455	CcSEcCtD
Ezetimibe—Dizziness—Epirubicin—ovarian cancer	6.52e-05	0.000453	CcSEcCtD
Ezetimibe—Pruritus—Doxorubicin—ovarian cancer	6.46e-05	0.000448	CcSEcCtD
Ezetimibe—Vomiting—Epirubicin—ovarian cancer	6.27e-05	0.000435	CcSEcCtD
Ezetimibe—Diarrhoea—Doxorubicin—ovarian cancer	6.24e-05	0.000434	CcSEcCtD
Ezetimibe—Rash—Epirubicin—ovarian cancer	6.22e-05	0.000432	CcSEcCtD
Ezetimibe—Dermatitis—Epirubicin—ovarian cancer	6.21e-05	0.000431	CcSEcCtD
Ezetimibe—Headache—Epirubicin—ovarian cancer	6.18e-05	0.000429	CcSEcCtD
Ezetimibe—Dizziness—Doxorubicin—ovarian cancer	6.04e-05	0.000419	CcSEcCtD
Ezetimibe—Nausea—Epirubicin—ovarian cancer	5.86e-05	0.000407	CcSEcCtD
Ezetimibe—Vomiting—Doxorubicin—ovarian cancer	5.8e-05	0.000403	CcSEcCtD
Ezetimibe—Rash—Doxorubicin—ovarian cancer	5.75e-05	0.0004	CcSEcCtD
Ezetimibe—Dermatitis—Doxorubicin—ovarian cancer	5.75e-05	0.000399	CcSEcCtD
Ezetimibe—Headache—Doxorubicin—ovarian cancer	5.72e-05	0.000397	CcSEcCtD
Ezetimibe—Nausea—Doxorubicin—ovarian cancer	5.42e-05	0.000376	CcSEcCtD
Ezetimibe—SLCO1B1—Transmembrane transport of small molecules—TUBB3—ovarian cancer	5.39e-05	0.000683	CbGpPWpGaD
Ezetimibe—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—ovarian cancer	5.32e-05	0.000674	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—CAV1—ovarian cancer	5.32e-05	0.000674	CbGpPWpGaD
Ezetimibe—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	5.3e-05	0.000671	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	5.17e-05	0.000654	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—NME2—ovarian cancer	5.15e-05	0.000652	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—CAV1—ovarian cancer	5.12e-05	0.000649	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.09e-05	0.000644	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—FASN—ovarian cancer	5.05e-05	0.000639	CbGpPWpGaD
Ezetimibe—ABCG2—Transmembrane transport of small molecules—TUBB3—ovarian cancer	4.99e-05	0.000632	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—SLC5A5—ovarian cancer	4.97e-05	0.000629	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—BRIP1—ovarian cancer	4.95e-05	0.000626	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—PPP1CC—ovarian cancer	4.95e-05	0.000626	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—PIK3CB—ovarian cancer	4.9e-05	0.00062	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.9e-05	0.00062	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—PIK3CG—ovarian cancer	4.85e-05	0.000614	CbGpPWpGaD
Ezetimibe—ABCC3—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	4.83e-05	0.000612	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—CYTB—ovarian cancer	4.81e-05	0.000609	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—CYTB—ovarian cancer	4.81e-05	0.000609	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—SLC2A1—ovarian cancer	4.8e-05	0.000607	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	4.72e-05	0.000597	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	4.7e-05	0.000596	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—PIK3CG—ovarian cancer	4.67e-05	0.000591	CbGpPWpGaD
Ezetimibe—ABCC3—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	4.67e-05	0.000591	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	4.61e-05	0.000584	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—CYP1B1—ovarian cancer	4.6e-05	0.000582	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—PIK3CD—ovarian cancer	4.26e-05	0.000539	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—PTEN—ovarian cancer	4.24e-05	0.000536	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	4.21e-05	0.000533	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—PPP1CC—ovarian cancer	4.21e-05	0.000533	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—BRIP1—ovarian cancer	4.21e-05	0.000533	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—PPP1CC—ovarian cancer	4.21e-05	0.000533	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—BRIP1—ovarian cancer	4.21e-05	0.000533	CbGpPWpGaD
Ezetimibe—ABCG2—HIF-1-alpha transcription factor network—AKT1—ovarian cancer	4.12e-05	0.000521	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—PIK3CD—ovarian cancer	4.1e-05	0.000519	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—PPP2R1A—ovarian cancer	4.08e-05	0.000516	CbGpPWpGaD
Ezetimibe—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—ovarian cancer	4.07e-05	0.000516	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	3.95e-05	0.0005	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—CYTB—ovarian cancer	3.91e-05	0.000495	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	3.85e-05	0.000487	CbGpPWpGaD
Ezetimibe—ABCC2—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	3.83e-05	0.000485	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—ABCB1—ovarian cancer	3.79e-05	0.00048	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—TYMS—ovarian cancer	3.72e-05	0.000471	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—CXCL8—ovarian cancer	3.72e-05	0.000471	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—PIK3CB—ovarian cancer	3.72e-05	0.00047	CbGpPWpGaD
Ezetimibe—ABCC2—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	3.7e-05	0.000468	CbGpPWpGaD
Ezetimibe—ABCC3—Transmembrane transport of small molecules—ABCB1—ovarian cancer	3.68e-05	0.000466	CbGpPWpGaD
Ezetimibe—SLCO1B1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	3.6e-05	0.000455	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—CYTB—ovarian cancer	3.58e-05	0.000454	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—PIK3CB—ovarian cancer	3.58e-05	0.000453	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	3.57e-05	0.000452	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—AQP3—ovarian cancer	3.56e-05	0.000451	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—CASP3—ovarian cancer	3.56e-05	0.000451	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—IL2—ovarian cancer	3.56e-05	0.00045	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	3.5e-05	0.000443	CbGpPWpGaD
Ezetimibe—ABCB1—HIF-1-alpha transcription factor network—VEGFA—ovarian cancer	3.49e-05	0.000442	CbGpPWpGaD
Ezetimibe—SLCO1B1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	3.47e-05	0.00044	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	3.46e-05	0.000438	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PPP1CC—ovarian cancer	3.42e-05	0.000433	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—BRIP1—ovarian cancer	3.42e-05	0.000433	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—ATP7B—ovarian cancer	3.41e-05	0.000432	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	3.4e-05	0.00043	CbGpPWpGaD
Ezetimibe—ABCG2—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	3.33e-05	0.000422	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—CYTB—ovarian cancer	3.32e-05	0.00042	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—YAP1—ovarian cancer	3.32e-05	0.00042	CbGpPWpGaD
Ezetimibe—ABCG2—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	3.22e-05	0.000407	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—PTEN—ovarian cancer	3.21e-05	0.000406	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PPP1CC—ovarian cancer	3.13e-05	0.000397	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—BRIP1—ovarian cancer	3.13e-05	0.000397	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—PTEN—ovarian cancer	3.09e-05	0.000391	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3.07e-05	0.000388	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—VEGFA—ovarian cancer	3.02e-05	0.000382	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—CAV1—ovarian cancer	3e-05	0.000379	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—PIK3CA—ovarian cancer	2.99e-05	0.000378	CbGpPWpGaD
Ezetimibe—ABCC2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	2.92e-05	0.00037	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PPP1CC—ovarian cancer	2.9e-05	0.000367	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—BRIP1—ovarian cancer	2.9e-05	0.000367	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—YAP1—ovarian cancer	2.82e-05	0.000357	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—YAP1—ovarian cancer	2.82e-05	0.000357	CbGpPWpGaD
Ezetimibe—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	2.81e-05	0.000356	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.79e-05	0.000354	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—NME2—ovarian cancer	2.78e-05	0.000352	CbGpPWpGaD
Ezetimibe—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	2.78e-05	0.000351	CbGpPWpGaD
Ezetimibe—SLCO1B1—Transmembrane transport of small molecules—ABCB1—ovarian cancer	2.74e-05	0.000347	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—PIK3CG—ovarian cancer	2.73e-05	0.000346	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—FASN—ovarian cancer	2.71e-05	0.000342	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—TUBB3—ovarian cancer	2.7e-05	0.000342	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—SLC5A5—ovarian cancer	2.66e-05	0.000337	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	2.64e-05	0.000334	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—SLC2A1—ovarian cancer	2.57e-05	0.000325	CbGpPWpGaD
Ezetimibe—ABCG2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	2.54e-05	0.000322	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	2.49e-05	0.000316	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—CYP1B1—ovarian cancer	2.46e-05	0.000312	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.46e-05	0.000311	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—AKT1—ovarian cancer	2.44e-05	0.000309	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—PIK3CD—ovarian cancer	2.4e-05	0.000304	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—FASN—ovarian cancer	2.3e-05	0.000291	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—FASN—ovarian cancer	2.3e-05	0.000291	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—YAP1—ovarian cancer	2.29e-05	0.00029	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.28e-05	0.000289	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—PIK3CA—ovarian cancer	2.26e-05	0.000287	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—SLC5A5—ovarian cancer	2.26e-05	0.000286	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—SLC5A5—ovarian cancer	2.26e-05	0.000286	CbGpPWpGaD
Ezetimibe—ABCB1—HIF-1-alpha transcription factor network—AKT1—ovarian cancer	2.23e-05	0.000282	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—SLC2A1—ovarian cancer	2.19e-05	0.000277	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—PPP2R1A—ovarian cancer	2.19e-05	0.000277	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—SLC2A1—ovarian cancer	2.19e-05	0.000277	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—PIK3CA—ovarian cancer	2.18e-05	0.000276	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.14e-05	0.000271	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—YAP1—ovarian cancer	2.1e-05	0.000266	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—CYP1B1—ovarian cancer	2.1e-05	0.000265	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—CYP1B1—ovarian cancer	2.1e-05	0.000265	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—PIK3CB—ovarian cancer	2.09e-05	0.000265	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.08e-05	0.000263	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—ABCB1—ovarian cancer	2.03e-05	0.000257	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—TYMS—ovarian cancer	1.99e-05	0.000252	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—YAP1—ovarian cancer	1.95e-05	0.000246	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	1.94e-05	0.000245	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—FASN—ovarian cancer	1.87e-05	0.000237	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—PPP2R1A—ovarian cancer	1.86e-05	0.000235	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—PPP2R1A—ovarian cancer	1.86e-05	0.000235	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—AKT1—ovarian cancer	1.85e-05	0.000234	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.85e-05	0.000234	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—SLC5A5—ovarian cancer	1.84e-05	0.000233	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.83e-05	0.000231	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—PTEN—ovarian cancer	1.81e-05	0.000229	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	1.8e-05	0.000228	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—CYTB—ovarian cancer	1.79e-05	0.000227	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	1.79e-05	0.000227	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—AKT1—ovarian cancer	1.78e-05	0.000225	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—SLC2A1—ovarian cancer	1.78e-05	0.000225	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	1.76e-05	0.000222	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	1.74e-05	0.00022	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—ABCB1—ovarian cancer	1.73e-05	0.000218	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—ABCB1—ovarian cancer	1.73e-05	0.000218	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—NME2—ovarian cancer	1.72e-05	0.000217	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—FASN—ovarian cancer	1.71e-05	0.000217	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	1.71e-05	0.000216	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—CYP1B1—ovarian cancer	1.7e-05	0.000216	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—TYMS—ovarian cancer	1.69e-05	0.000214	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—TYMS—ovarian cancer	1.69e-05	0.000214	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	1.69e-05	0.000214	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—SLC5A5—ovarian cancer	1.69e-05	0.000213	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	1.65e-05	0.000209	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—SLC2A1—ovarian cancer	1.63e-05	0.000206	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—CAV1—ovarian cancer	1.61e-05	0.000203	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.59e-05	0.000202	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—FASN—ovarian cancer	1.59e-05	0.000201	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PPP1CC—ovarian cancer	1.57e-05	0.000199	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—BRIP1—ovarian cancer	1.57e-05	0.000199	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—CYP1B1—ovarian cancer	1.56e-05	0.000197	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—SLC5A5—ovarian cancer	1.56e-05	0.000197	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PPP2R1A—ovarian cancer	1.51e-05	0.000191	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—SLC2A1—ovarian cancer	1.51e-05	0.000191	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	1.49e-05	0.000189	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—PIK3CG—ovarian cancer	1.46e-05	0.000185	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—CYP1B1—ovarian cancer	1.44e-05	0.000183	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	1.41e-05	0.000179	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—ABCB1—ovarian cancer	1.4e-05	0.000177	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PPP2R1A—ovarian cancer	1.38e-05	0.000175	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—TYMS—ovarian cancer	1.38e-05	0.000174	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.38e-05	0.000174	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	1.37e-05	0.000174	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—CAV1—ovarian cancer	1.37e-05	0.000173	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—CAV1—ovarian cancer	1.37e-05	0.000173	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	1.34e-05	0.00017	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	1.34e-05	0.00017	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.3e-05	0.000165	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—PIK3CD—ovarian cancer	1.29e-05	0.000163	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—ABCB1—ovarian cancer	1.28e-05	0.000163	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PPP2R1A—ovarian cancer	1.28e-05	0.000162	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—PIK3CA—ovarian cancer	1.28e-05	0.000161	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	1.27e-05	0.00016	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—TYMS—ovarian cancer	1.26e-05	0.00016	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—PIK3CG—ovarian cancer	1.24e-05	0.000157	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—PIK3CG—ovarian cancer	1.24e-05	0.000157	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—ABCB1—ovarian cancer	1.19e-05	0.000151	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—TYMS—ovarian cancer	1.17e-05	0.000148	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	1.16e-05	0.000147	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	1.13e-05	0.000143	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—PIK3CB—ovarian cancer	1.12e-05	0.000142	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—CAV1—ovarian cancer	1.11e-05	0.00014	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—CYTB—ovarian cancer	1.11e-05	0.00014	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—PIK3CD—ovarian cancer	1.09e-05	0.000138	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—PIK3CD—ovarian cancer	1.09e-05	0.000138	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—YAP1—ovarian cancer	1.05e-05	0.000133	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—AKT1—ovarian cancer	1.04e-05	0.000132	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—CAV1—ovarian cancer	1.02e-05	0.000129	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PIK3CG—ovarian cancer	1.01e-05	0.000128	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	9.71e-06	0.000123	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—PTEN—ovarian cancer	9.69e-06	0.000123	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—BRIP1—ovarian cancer	9.66e-06	0.000122	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PPP1CC—ovarian cancer	9.66e-06	0.000122	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—PIK3CB—ovarian cancer	9.53e-06	0.000121	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—PIK3CB—ovarian cancer	9.53e-06	0.000121	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	9.51e-06	0.00012	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—CAV1—ovarian cancer	9.42e-06	0.000119	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PIK3CG—ovarian cancer	9.26e-06	0.000117	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PIK3CD—ovarian cancer	8.89e-06	0.000112	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—FASN—ovarian cancer	8.58e-06	0.000109	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PIK3CG—ovarian cancer	8.58e-06	0.000109	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—SLC5A5—ovarian cancer	8.44e-06	0.000107	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—PTEN—ovarian cancer	8.24e-06	0.000104	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—PTEN—ovarian cancer	8.24e-06	0.000104	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—SLC2A1—ovarian cancer	8.15e-06	0.000103	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PIK3CD—ovarian cancer	8.14e-06	0.000103	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—CYP1B1—ovarian cancer	7.81e-06	9.89e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PIK3CB—ovarian cancer	7.74e-06	9.8e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PIK3CD—ovarian cancer	7.54e-06	9.54e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PIK3CB—ovarian cancer	7.1e-06	8.98e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PPP2R1A—ovarian cancer	6.93e-06	8.77e-05	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—PIK3CA—ovarian cancer	6.83e-06	8.65e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PTEN—ovarian cancer	6.69e-06	8.47e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PIK3CB—ovarian cancer	6.57e-06	8.32e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—YAP1—ovarian cancer	6.48e-06	8.2e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—TYMS—ovarian cancer	6.32e-06	8e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PTEN—ovarian cancer	6.13e-06	7.76e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—PIK3CA—ovarian cancer	5.81e-06	7.35e-05	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—PIK3CA—ovarian cancer	5.81e-06	7.35e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PTEN—ovarian cancer	5.68e-06	7.19e-05	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—AKT1—ovarian cancer	5.58e-06	7.07e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—FASN—ovarian cancer	5.28e-06	6.69e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—SLC5A5—ovarian cancer	5.2e-06	6.58e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—CAV1—ovarian cancer	5.09e-06	6.44e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—SLC2A1—ovarian cancer	5.02e-06	6.35e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—CYP1B1—ovarian cancer	4.81e-06	6.09e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—AKT1—ovarian cancer	4.75e-06	6.01e-05	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—AKT1—ovarian cancer	4.75e-06	6.01e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PIK3CA—ovarian cancer	4.72e-06	5.98e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PIK3CG—ovarian cancer	4.64e-06	5.87e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PIK3CA—ovarian cancer	4.33e-06	5.48e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	4.27e-06	5.4e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PIK3CD—ovarian cancer	4.08e-06	5.16e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PIK3CA—ovarian cancer	4.01e-06	5.07e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—ABCB1—ovarian cancer	3.96e-06	5.02e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—TYMS—ovarian cancer	3.89e-06	4.93e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—AKT1—ovarian cancer	3.86e-06	4.88e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PIK3CB—ovarian cancer	3.55e-06	4.5e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—AKT1—ovarian cancer	3.53e-06	4.47e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—AKT1—ovarian cancer	3.27e-06	4.14e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—CAV1—ovarian cancer	3.14e-06	3.97e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PTEN—ovarian cancer	3.07e-06	3.89e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PIK3CG—ovarian cancer	2.86e-06	3.62e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PIK3CD—ovarian cancer	2.51e-06	3.18e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PIK3CB—ovarian cancer	2.19e-06	2.77e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PIK3CA—ovarian cancer	2.17e-06	2.74e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PTEN—ovarian cancer	1.89e-06	2.39e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—AKT1—ovarian cancer	1.77e-06	2.24e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.33e-06	1.69e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—AKT1—ovarian cancer	1.09e-06	1.38e-05	CbGpPWpGaD
